View Exam | PowerPak

1. Which of the following would constitute a major or severe bleeding episode that would require the use of a specific DOAC reversal agent?

A. Bleeding with hemodynamic stability B. Bleeding events causing a hemoglobin drop ≥ 1.5 g/dL C. Bleeding of the intraluminal GI tract D. Retroperitoneal bleeding E. Not sure

2. Which of the following would preclude the prompt reinitiation of oral anticoagulant therapy following DOAC reversal?

A. Patient has a surgical/invasive procedure planned B. Patient is not at high risk of rebleeding or of death/disability with rebleeding C. Patient is experiencing bleeding at a non-critical, previously known site of bleeding D. Patient with original indication for anticoagulation with high thrombotic risk E. Not sure

3. Which of the following represents the most accurate statement regarding the use of specific and nonspecific DOAC reversal agents?

A. The ACC/ACEP guidelines recommend interchangeable use of prothrombin complex concentrate (PCC) or factor eight inhibitor bypassing activity (FEIBA) with the specific reversal agents, idarucizumab and andexanet alfa B. PCC is recommended as a first-line agent for reversal of dabigatran C. Andexanet alfa is recommended as a first-line agent for reversal of apixaban and rivaroxaban D. Idarucizumab is recommended as a first-line agent for reversal of apixaban E. Not sure

4. A 68-year-old male with a history of hypertension and atrial fibrillation presents to the emergency department (ED) with a chief complaint of headache, weakness, and dizziness. Evaluation shows an intracranial hemorrhage (ICH). You are able to confirm from his medication history that he was taking 20 mg of rivaroxaban once daily and took his last dose about 6 hours ago. Which reversal strategy would be most appropriate for this patient?

A. 4-factor prothrombin complex concentrate (4F-PCC) at 25 U/kg IV B. Idarucizumab 5 g IV bolus C. Andexanet alfa 400 mg (30 mg/min) IV bolus + 4 mg/min for up to 120 minutes D. Andexanet alfa 800 mg (30 mg/min) IV bolus + 8 mg/min for 120 minutes E. Not sure

Scheduled Maintenance to Improve Performance & Reliability

10/17/2024 4:00 PM EST - 10/17/2024 11:59 PM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following would constitute a major or severe bleeding episode that would require the use of a specific DOAC reversal agent?

2. Which of the following would preclude the prompt reinitiation of oral anticoagulant therapy following DOAC reversal?

3. Which of the following represents the most accurate statement regarding the use of specific and nonspecific DOAC reversal agents?

« Return to Activity

Scheduled Maintenance to Improve Performance & Reliability

10/17/2024 4:00 PM EST - 10/17/2024 11:59 PM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following would constitute a major or severe bleeding episode that would require the use of a specific DOAC reversal agent?

2. Which of the following would preclude the prompt reinitiation of oral anticoagulant therapy following DOAC reversal?

3. Which of the following represents the most accurate statement regarding the use of specific and nonspecific DOAC reversal agents?

« Return to Activity

Customers who Purchased
this Activity also Purchased